Kissei Of Japan Obtains U.S. FDA Approval For PBH Drug Silodosin
This article was originally published in PharmAsia News
Japanese drug maker Kissei announced Oct. 9 that urination disorder drug Urief (silodosin) has obtained a new drug approval from U.S. FDA. Originally developed by Kissei, silodosin is an alpha 1A adrengergic receptor antagonist that improves the signs and symptoms of benign prostatic hyperplasia, such as weak stream and frequency and urgency of urination. In clinical studies, silodosin was shown to relieve symptoms faster compared to current products. Half of American males aged 60 years and over are estimated to have BPH. Silodosin will be marketed as Rapiflo in the United States (Click here for more - Japanese language
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.